Schizophrenia - Articles - Page 3

RESEARCH UPDATE

Metacognitive Therapy Shows Potential in Treating Schizophrenia

February 2, 2024

Batya Swift, MA, LSW. Ms Swift has no financial relationships with companies related to this material.

A recent study explores a patient-centric approach designed to enhance understanding of self and others, potentially transforming the landscape of schizophrenia treatment.

Research Update

Immediate vs Extended-Release Quetiapine for Schizophrenia

January 1, 2024

Richard Moldawsky, MD

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

A new analysis looks at the optimal dosing for quetiapine in schizophrenia, and when to use instant vs extended release.

Clinical Update

Negative Symptoms of Schizophrenia

January 1, 2024

Chris Aiken, MD and Paul Riordan, MD.

Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report. Assistant Professor, NYU Langone Department of Psychiatry. Practicing psychiatrist, Winston-Salem, NC.

Paul Riordan, MD. Assistant Consulting Professor of Psychiatry, Duke University, Durham, NC.

The authors have no financial relationships with companies related to this material.

Negative symptoms are the primary cause of disability in schizophrenia, and we identify a few antipsychotics and a few add-on therapies that can help.

Research Update

Long-Acting Injectable Antipsychotics and Risk of Hospitalization

October 3, 2023

Brian Holoyda, MD, MPH, MBA

Brian Holoyda, MD. Dr. Holoyda has no financial relationships with companies related to this material.

By initiating LAIs early in the course of a patient’s illness, we can significantly delay the time to first hospitalization in young adults.

Clinical Update

How to Identify and Treat Prodromal Symptoms of Bipolar Disorder and Schizophrenia

September 1, 2023

José S. Sanchez-Cruz, MD

José S. Sanchez-Cruz, MD. Chief Resident, Department of Psychiatry, NYU Langone Health, New York. Chris Aiken, MD. Editor-in-Chief, The Carlat Psychiatry Report; Assistant Professor, NYU Langone Department of Psychiatry; practicing psychiatrist, Winston-Salem, NC.

Dr. Sanchez-Cruz and Dr. Aiken have no financial relationships with companies related to this material.

Patients with genetic risks for schizophrenia and bipolar disorder often present with prodromal symptoms of the illness, but the most effective treatment may surprise some. It’s not a medication.

CARLAT WEBINAR

A Primer on Delusional Misidentification Syndromes

July 6, 2023

Victoria Hendrick, MD

0.50 CME Credits. Explore the clinical presentations, prevalence, underlying factors, and management approaches associated with delusional misidentification syndromes.

Research Update

Probiotics, Dietary Fiber, and Antipsychotic Weight Gain

July 3, 2023

Jeffrey Cardenas, MD

Jeffrey Cardenas, MD. Dr. Cardenas has no financial relationships with companies related to this material.

Probiotics may reduce metabolic side effects on antipsychotics, but do they need dietary fiber to work?

Expert Q&A

Recognizing and Treating Psychosis in Autism

April 1, 2023

Kristin Cadenhead, MD

Kristin Cadenhead, MD.

Professor of psychiatry. Director, Cognitive Assessment and Risk Evaluation (CARE) Early Psychosis Treatment and Research Program, University of California, San Diego.

Dr. Cadenhead has no financial relationships with companies related to this material.

Is it autism or psychosis or both? Autistic traits and psychotic symptoms can look a lot alike. How common is psychosis in autism? And how can we differentiate co-occurring autistic traits from psychotic symptoms? Dr. Kristin Cadenhead gives us an approach for sorting through the history and addressing these problems separately.

BOOK REVIEWS FOR PSYCHIATRISTS

Using Stories to Color the Stark Lines of Evidence-Based Medicine: Elyn R. Saks

February 9, 2023

Emily E. Whisler, DO and Edmund S. Higgins, MD.

The first in a series of interesting reading for psychiatrists

RESEARCH UPDATE

Pimavanserin Improves Negative Symptoms of Schizophrenia

January 1, 2023

Brian Miller, MD, PhD, MPH

Brian Miller, MD, PhD, MPH. Dr. Miller, author of this educational activity, receives research support from Augusta University, the National Institute of Mental Health, the Brain and Behavior Research Foundation, and the Stanley Medical Research Institute. Relevant financial relationships listed for the author have been mitigated.

Pimavanserin (Nuplazid) is a novel antipsychotic with a narrow FDA-approval in psychosis due to Parkinson’s disease. This large randomized trial tested the drug in negative symptoms of
schizophrenia.